BioGaia’s result for second quarter to exceed market expectations

(Figures in brackets refer to the same period the previous year)

BioGaia´s sales for the second quarter has been positively impacted by an increased demand mainly from the European market.

Sales for the second quarter are preliminarily estimated at SEK 288 million (203), up 42%. Operating profit for the second quarter is preliminarily estimated at SEK 101 million (69), up 46%.

BioGaia will publish the interim report for the second quarter on Friday, 22 July 2022 at 08:00 a.m., followed by a teleconference at 09:30 a.m.

Latest press releases from BioGaia:

01.07.2022 BioGaia launches probiotic product to support children’s respiratory health

08.06.2022 BioGaia signs exclusive agreement in South Korea for the baby gut health range

31.05.2022 New number of shares and votes in BioGaia AB (publ)

This disclosure contains information that BioGaia is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 14-07-2022 08:00 CET.

For more information, please contact
Alexander Kotsinas, CFO: +46 8 555 293 00

BioGaia is an innovative Swedish healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are sold through local distribution partners in more than 100 countries worldwide. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm. biogaia.com